Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by RAWCOLTYon Feb 10, 2020 10:56am
79 Views
Post# 30667623

RE:RE:RE:Yahoo finance

RE:RE:RE:Yahoo finance I agree with St. Francine, just have to be patient. I did sell some shares to buy something else cheap right now. We will have time with this stock now, unfortunately, that is why money is leaving. Idle money always finds a better home that is why we are getting crushed today. Only problem is that they are vulverable to a takeout. Management is stresssed out and could accept a stink bid for say around $1.50 per share cash just to end their headache. I will maintain my half position from now until the end.

Management compinsated themselves handsomely over the years and this happens. The top people in charge should be forced out immediately by the Board if possible. They had one job to accomplish the last 8 months and they failed. Wheather the resullts were skewed by accident or on purpose This management team should be removed to build back some faith in the Company.

Bullboard Posts